| Original language | English |
|---|---|
| Pages (from-to) | 1934-1937.e4 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 143 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2019 |
| Externally published | Yes |
Funding
| Funders | Funder number |
|---|---|
| APAAACI | |
| Aerocrine | |
| American Board of Pediatrics | |
| American College of Chest Physicians | |
| AsthmaNet | |
| Corbus Pharmaceuticals | |
| DBV Technologies | |
| Genentech/Novartis | |
| Japanese Society of Allergology | |
| NHLBI AsthmaNet | |
| NIH/NHLBI | |
| NIH/NIAID | |
| NIH/National Institute of Environmental Health Sciences | |
| Novartis/Regeneron | |
| Pneuma Respiratory | |
| Quintiles | |
| Sanofi/Regeneron | |
| UpToDate | |
| National Institutes of Health | |
| National Heart, Lung, and Blood Institute | U10HL098112 |
| National Heart, Lung, and Blood Institute | |
| National Institute of Allergy and Infectious Diseases | |
| National Institute of Environmental Health Sciences | |
| Cystic Fibrosis Foundation | |
| Boehringer Ingelheim | |
| American Academy of Allergy Asthma and Immunology | |
| American Lung Association | |
| Pfizer | |
| AstraZeneca | |
| Genentech | |
| GlaxoSmithKline | |
| Johnson and Johnson | |
| Merck | |
| Novartis | |
| Roche | |
| Sanofi | |
| Gilead Sciences | |
| North Carolina GlaxoSmithKline Foundation | |
| Patient-Centered Outcomes Research Institute | |
| Teva Pharmaceutical Industries | |
| Chiesi Farmaceutici | |
| Feinberg School of Medicine | |
| Boston Scientific Corporation | |
| Sunovion | |
| Regeneron Pharmaceuticals | |
| Vertex Pharmaceuticals | |
| Sanofi Genzyme | |
| Daiichi Sankyo Company | |
| European Academy of Allergy and Clinical Immunology | |
| Norges Idrettshøgskole |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology, Vol. 143, No. 5, 05.2019, p. 1934-1937.e4.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children
AU - National Heart, Lung, and Blood Institute's AsthmaNet
AU - Guilbert, Theresa W.
AU - Bacharier, Leonard B.
AU - Mauger, David T.
AU - Phipatanakul, Wanda
AU - Szefler, Stanley J.
AU - Boehmer, Susan
AU - Beigelman, Avraham
AU - Fitzpatrick, Anne M.
AU - Jackson, Daniel J.
AU - Baxi, Sachin N.
AU - Benson, Mindy
AU - Burnham, Carey Ann D.
AU - Cabana, Michael D.
AU - Castro, Mario
AU - Chmiel, James F.
AU - Covar, Ronina
AU - Daines, Michael
AU - Gaffin, Jonathan M.
AU - Gentile, Deborah A.
AU - Holguin, Fernando
AU - Israel, Elliot
AU - Kelly, H. William
AU - Lazarus, Stephen C.
AU - Lemanske, Robert F.
AU - Ly, Ngoc
AU - Meade, Kelley
AU - Morgan, Wayne
AU - Moy, James
AU - Olin, J. Tod
AU - Peters, Stephen P.
AU - Pongracic, Jacqueline A.
AU - Raissy, Hengameh H.
AU - Ross, Kristie
AU - Sheehan, William J.
AU - Sorkness, Christine
AU - Teague, W. Gerald
AU - Thyne, Shannon
AU - Martinez, Fernando D.
AU - Bartnikas, Lisa
AU - Bouzaher, Alisha
AU - Burke, Christopher
AU - Cavanaugh, Matthew
AU - Chen, Julia
AU - Cunningham, Elizabeth
AU - Cunningham, Amparito
AU - Friedlander, James
AU - Hindi, Enal
AU - Kantor, David
AU - Permaul, Perdita
AU - Rao, Devako
N1 - Funding Information: Disclosure of potential conflict of interest: T. W. Guilbert reports personal fees from the American Board of Pediatrics–Pediatric Pulmonary Subboard, GlaxoSmithKline, Regeneron Pharmaceuticals, Merck, Novartis/Regeneron, Aviragen, GlaxoSmithKline/Regneron, and TEVA; grants from the National Institutes of Health (NIH); grants and personal fees from Sanofi / Regenero ; and other support from UpToDate outside the submitted work. L. B. Bacharier reports grants from the NIH during the conduct of the study and reports personal fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia outside the submitted work. D. T. Mauger reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study and has received nonfinancial support from GlaxoSmithKline , Merck , TEVA , and Boehringer Ingelheim outside the submitted work. W. Phipatanakul reports grants from the NIH during the conduct of the study, reports grants and other support from Genentech and GlaxoSmithKline , and reports other support from Novartis , Teva , and Sanofi / Regeneron . S. J. Szefler reports grants and other from NHLBI AsthmaNet during the conduct of the study and reports grants from GlaxoSmithKline and other support from Boehringer Ingelheim , Genentech , GlaxoSmithKline , Aerocrine , AstraZeneca , Daiichi Sankyo , Roche , Teva , and Propeller Health outside the submitted work. A. Beigelman and A. M. Fitzpatrick report grants from the NIH during the conduct of the study. D. J. Jackson reports grants from the NHLBI during the conduct of the study and reports grants from the National Institute of Allergy and Infectious Diseases (NIAID), personal fees from Vectura, Boehringer Ingelheim, and Pfizer, and grants and personal fees from GlaxoSmithKline outside the submitted work. M. D. Cabana reports personal fees from Novartis, Genentech, and Phadea outside the submitted work. M. Castro receives University Grant Funding from the NIH , American Lung Association , and PCORI ; receives pharmaceutical grant funding from AstraZeneca , Boehringer Ingelheim , Chiesi , GlaxoSmithKline , Novartis , and Sanofi Aventis; is a consultant for Aviragen, Boston Scientific, Genentech, Nuvaira, Neutronic, Therabron, Theravance, Vectura, 4D Pharma, VIDA, Mallincrodt, Teva, and Sanofi-Aventis; is a speaker for AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, Regeneron, Sanofi, and Teva; and receives royalties from Elsevier. J. F. Chmiel reports grants from the NIH during the conduct of the study and reports personal fees from the American Board of Pediatrics, the Cystic Fibrosis Foundation, Albumedix, Catabasis, Patara Pharma, and Paka Pharma; reports nonfinancial support from GlaxoSmithKline , Teva , Merck , Sunovion , Corbus Pharmaceuticals , and Vertex Pharmaceuticals ; and reports grants from the Cystic Fibrosis Foundation outside the submitted work. R. Covar reports grants from GlaxoSmithKline and Novartis outside the submitted work. E. Israel reports personal fees from AstraZeneca , Novartis , Regeneron Pharmaceuticals , Bird Rock Bio , Nuvelution Pharmaceuticals , Vitaeris , Sanofi Genzyme , Merck , Entrinsic Health Solutions , GlaxoSmithKline , Pneuma Respiratory , 4D Pharma, Sienna Biopharmaceutical, and Equillium; reports personal fees and other from TEVA Specialty Pharmaceuticals; reports grants from Genentech , Sanofi , and Boehringer Ingelheim ; reports nonfinancial support from Boehringer Ingelheim , GlaxoSmithKline , Merck , Sunovion , TEVA, and TEVA Specialty Pharmaceuticals; and reports other support from Vorso Corp outside the submitted work. S. C. Lazarus reports grants from the NIH / NHLBI during the conduct of the study. R. F. Lemanske, Jr, reports grants from the NHLBI during the conduct of the study; reports nonfinancial support from the American Academy of Allergy, Asthma & Immunology; reports grants from the Clinical and Translational Science Award from the NIH , Childhood Origins of Asthma (COAST), and AsthmaNet; and reports personal fees from LSU, Elsevier, UpToDate, the EAACI, the Japanese Society of Allergology, and the APAAACI and APAPARI outside the submitted work. N. Ly reports grants from Vertex 2018 and Vertex 2017 and personal fees from Gilead and has a patent null pending. W. Morgan reports grants from the NIH / NHLBI during the conduct of the study and reports grants from the Cystic Fibrosis Foundation , the NIH / NIAID and the NIH / NHLBI ; and reports personal fees from Genentech , the Cystic Fibrosis Foundation , and the American College of Chest Physicians outside the submitted work. J. Moy reports grants from the NIH / NHLBI during the conduct of the study. S. P. Peters reports grants from the NIH / NHLBI during the conduct of the study and reports personal fees from AstraZeneca, Regeneron-Sanofi, Genentech, TEVA, Quintiles, Novartis, and Mylan outside the submitted work. J. A. Pongracic reports grants from the NHLBI (subcontract through Northwestern University Feinberg School of Medicine ) during the conduct of the study and reports other support from GlaxoSmithKline and Novartis outside the submitted work. K. Ross reports nonfinancial support from Boehringer Ingelheim , GlaxoSmithKline , and Merck ; grants and nonfinancial support from TEVA ; and grants from Flamel , Jazz , and the NHLBI outside the submitted work. C. Sorkness reports grants from the NIAID and NHLBI during the conduct of the study. W. G. Teague reports grants from the NIH / NHLBI and TEVA Respiratory and personal fees from Genentech outside the submitted work. F. D. Martinez reports grants from the NIH / NHLBI during the conduct of the study; reports grants from the NIH / NHLBI , NIH / National Institute of Environmental Health Sciences , NIH / NIAID , and NIH /Office of Director, and Johnson & Johnson ; and reports personal fees from Copeval and Commense outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor Funding Information: Disclosure of potential conflict of interest: T. W. Guilbert reports personal fees from the American Board of Pediatrics?Pediatric Pulmonary Subboard, GlaxoSmithKline, Regeneron Pharmaceuticals, Merck, Novartis/Regeneron, Aviragen, GlaxoSmithKline/Regneron, and TEVA; grants from the National Institutes of Health (NIH); grants and personal fees from Sanofi/Regenero; and other support from UpToDate outside the submitted work. L. B. Bacharier reports grants from the NIH during the conduct of the study and reports personal fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia outside the submitted work. D. T. Mauger reports grants from the National Heart, Lung, and Blood Institute (NHLBI)during the conduct of the study and has received nonfinancial support from GlaxoSmithKline, Merck, TEVA, and Boehringer Ingelheim outside the submitted work. W. Phipatanakul reports grants from the NIH during the conduct of the study, reports grants and other support from Genentech and GlaxoSmithKline, and reports other support from Novartis, Teva, and Sanofi/Regeneron. S. J. Szefler reports grants and other from NHLBI AsthmaNet during the conduct of the study and reports grants from GlaxoSmithKline and other support from Boehringer Ingelheim, Genentech, GlaxoSmithKline, Aerocrine, AstraZeneca, Daiichi Sankyo, Roche, Teva, and Propeller Health outside the submitted work. A. Beigelman and A. M. Fitzpatrick report grants from the NIH during the conduct of the study. D. J. Jackson reports grants from the NHLBI during the conduct of the study and reports grants from the National Institute of Allergy and Infectious Diseases (NIAID), personal fees from Vectura, Boehringer Ingelheim, and Pfizer, and grants and personal fees from GlaxoSmithKline outside the submitted work. M. D. Cabana reports personal fees from Novartis, Genentech, and Phadea outside the submitted work. M. Castro receives University Grant Funding from the NIH, American Lung Association, and PCORI; receives pharmaceutical grant funding from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Sanofi Aventis; is a consultant for Aviragen, Boston Scientific, Genentech, Nuvaira, Neutronic, Therabron, Theravance, Vectura, 4D Pharma, VIDA, Mallincrodt, Teva, and Sanofi-Aventis; is a speaker for AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, Regeneron, Sanofi, and Teva; and receives royalties from Elsevier. J. F. Chmiel reports grants from the NIH during the conduct of the study and reports personal fees from the American Board of Pediatrics, the Cystic Fibrosis Foundation, Albumedix, Catabasis, Patara Pharma, and Paka Pharma; reports nonfinancial support from GlaxoSmithKline, Teva, Merck, Sunovion, Corbus Pharmaceuticals, and Vertex Pharmaceuticals; and reports grants from the Cystic Fibrosis Foundation outside the submitted work. R. Covar reports grants from GlaxoSmithKline and Novartis outside the submitted work. E. Israel reports personal fees from AstraZeneca, Novartis, Regeneron Pharmaceuticals, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Sanofi Genzyme, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Pneuma Respiratory, 4D Pharma, Sienna Biopharmaceutical, and Equillium; reports personal fees and other from TEVA Specialty Pharmaceuticals; reports grants from Genentech, Sanofi, and Boehringer Ingelheim; reports nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, TEVA, and TEVA Specialty Pharmaceuticals; and reports other support from Vorso Corp outside the submitted work. S. C. Lazarus reports grants from the NIH/NHLBI during the conduct of the study. R. F. Lemanske, Jr, reports grants from the NHLBI during the conduct of the study; reports nonfinancial support from the American Academy of Allergy, Asthma & Immunology; reports grants from the Clinical and Translational Science Award from the NIH, Childhood Origins of Asthma (COAST), and AsthmaNet; and reports personal fees from LSU, Elsevier, UpToDate, the EAACI, the Japanese Society of Allergology, and the APAAACI and APAPARI outside the submitted work. N. Ly reports grants from Vertex 2018 and Vertex 2017 and personal fees from Gilead and has a patent null pending. W. Morgan reports grants from the NIH/NHLBI during the conduct of the study and reports grants from the Cystic Fibrosis Foundation, the NIH/NIAID and the NIH/NHLBI; and reports personal fees from Genentech, the Cystic Fibrosis Foundation, and the American College of Chest Physicians outside the submitted work. J. Moy reports grants from the NIH/NHLBI during the conduct of the study. S. P. Peters reports grants from the NIH/NHLBI during the conduct of the study and reports personal fees from AstraZeneca, Regeneron-Sanofi, Genentech, TEVA, Quintiles, Novartis, and Mylan outside the submitted work. J. A. Pongracic reports grants from the NHLBI (subcontract through Northwestern University Feinberg School of Medicine)during the conduct of the study and reports other support from GlaxoSmithKline and Novartis outside the submitted work. K. Ross reports nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, and Merck; grants and nonfinancial support from TEVA; and grants from Flamel, Jazz, and the NHLBI outside the submitted work. C. Sorkness reports grants from the NIAID and NHLBI during the conduct of the study. W. G. Teague reports grants from the NIH/NHLBI and TEVA Respiratory and personal fees from Genentech outside the submitted work. F. D. Martinez reports grants from the NIH/NHLBI during the conduct of the study; reports grants from the NIH/NHLBI, NIH/National Institute of Environmental Health Sciences, NIH/NIAID, and NIH/Office of Director, and Johnson & Johnson; and reports personal fees from Copeval and Commense outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Disclosure of potential conflict of interest: T. W. Guilbert reports personal fees from the American Board of Pediatrics–Pediatric Pulmonary Subboard, GlaxoSmithKline, Regeneron Pharmaceuticals, Merck, Novartis/Regeneron, Aviragen, GlaxoSmithKline/Regneron, and TEVA; grants from the National Institutes of Health (NIH); grants and personal fees from Sanofi/Regenero; and other support from UpToDate outside the submitted work. L. B. Bacharier reports grants from the NIH during the conduct of the study and reports personal fees from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia outside the submitted work. D. T. Mauger reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study and has received nonfinancial support from GlaxoSmithKline, Merck, TEVA, and Boehringer Ingelheim outside the submitted work. W. Phipatanakul reports grants from the NIH during the conduct of the study, reports grants and other support from Genentech and GlaxoSmithKline, and reports other support from Novartis, Teva, and Sanofi/Regeneron. S. J. Szefler reports grants and other from NHLBI AsthmaNet during the conduct of the study and reports grants from GlaxoSmithKline and other support from Boehringer Ingelheim, Genentech, GlaxoSmithKline, Aerocrine, AstraZeneca, Daiichi Sankyo, Roche, Teva, and Propeller Health outside the submitted work. A. Beigelman and A. M. Fitzpatrick report grants from the NIH during the conduct of the study. D. J. Jackson reports grants from the NHLBI during the conduct of the study and reports grants from the National Institute of Allergy and Infectious Diseases (NIAID), personal fees from Vectura, Boehringer Ingelheim, and Pfizer, and grants and personal fees from GlaxoSmithKline outside the submitted work. M. D. Cabana reports personal fees from Novartis, Genentech, and Phadea outside the submitted work. M. Castro receives University Grant Funding from the NIH, American Lung Association, and PCORI; receives pharmaceutical grant funding from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Sanofi Aventis; is a consultant for Aviragen, Boston Scientific, Genentech, Nuvaira, Neutronic, Therabron, Theravance, Vectura, 4D Pharma, VIDA, Mallincrodt, Teva, and Sanofi-Aventis; is a speaker for AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, Regeneron, Sanofi, and Teva; and receives royalties from Elsevier. J. F. Chmiel reports grants from the NIH during the conduct of the study and reports personal fees from the American Board of Pediatrics, the Cystic Fibrosis Foundation, Albumedix, Catabasis, Patara Pharma, and Paka Pharma; reports nonfinancial support from GlaxoSmithKline, Teva, Merck, Sunovion, Corbus Pharmaceuticals, and Vertex Pharmaceuticals; and reports grants from the Cystic Fibrosis Foundation outside the submitted work. R. Covar reports grants from GlaxoSmithKline and Novartis outside the submitted work. E. Israel reports personal fees from AstraZeneca, Novartis, Regeneron Pharmaceuticals, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Sanofi Genzyme, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Pneuma Respiratory, 4D Pharma, Sienna Biopharmaceutical, and Equillium; reports personal fees and other from TEVA Specialty Pharmaceuticals; reports grants from Genentech, Sanofi, and Boehringer Ingelheim; reports nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, TEVA, and TEVA Specialty Pharmaceuticals; and reports other support from Vorso Corp outside the submitted work. S. C. Lazarus reports grants from the NIH/NHLBI during the conduct of the study. R. F. Lemanske, Jr, reports grants from the NHLBI during the conduct of the study; reports nonfinancial support from the American Academy of Allergy, Asthma & Immunology; reports grants from the Clinical and Translational Science Award from the NIH, Childhood Origins of Asthma (COAST), and AsthmaNet; and reports personal fees from LSU, Elsevier, UpToDate, the EAACI, the Japanese Society of Allergology, and the APAAACI and APAPARI outside the submitted work. N. Ly reports grants from Vertex 2018 and Vertex 2017 and personal fees from Gilead and has a patent null pending. W. Morgan reports grants from the NIH/NHLBI during the conduct of the study and reports grants from the Cystic Fibrosis Foundation, the NIH/NIAID and the NIH/NHLBI; and reports personal fees from Genentech, the Cystic Fibrosis Foundation, and the American College of Chest Physicians outside the submitted work. J. Moy reports grants from the NIH/NHLBI during the conduct of the study. S. P. Peters reports grants from the NIH/NHLBI during the conduct of the study and reports personal fees from AstraZeneca, Regeneron-Sanofi, Genentech, TEVA, Quintiles, Novartis, and Mylan outside the submitted work. J. A. Pongracic reports grants from the NHLBI (subcontract through Northwestern University Feinberg School of Medicine) during the conduct of the study and reports other support from GlaxoSmithKline and Novartis outside the submitted work. K. Ross reports nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, and Merck; grants and nonfinancial support from TEVA; and grants from Flamel, Jazz, and the NHLBI outside the submitted work. C. Sorkness reports grants from the NIAID and NHLBI during the conduct of the study. W. G. Teague reports grants from the NIH/NHLBI and TEVA Respiratory and personal fees from Genentech outside the submitted work. F. D. Martinez reports grants from the NIH/NHLBI during the conduct of the study; reports grants from the NIH/NHLBI, NIH/National Institute of Environmental Health Sciences, NIH/NIAID, and NIH/Office of Director, and Johnson & Johnson; and reports personal fees from Copeval and Commense outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2019/5
Y1 - 2019/5
UR - http://www.scopus.com/inward/record.url?scp=85061157615&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2018.10.071
DO - 10.1016/j.jaci.2018.10.071
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30660645
AN - SCOPUS:85061157615
SN - 0091-6749
VL - 143
SP - 1934-1937.e4
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -